Risk Factors for Re-Excision Following Breast-Conserving Surgery

Rodriguez, Kimberly A.; Wilkins, Gayle G.; Newcomb, Patricia; Gwirtz, Patricia A.; Skrine, Robin

doi:10.1188/17.onf.358-365

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lingering tumor cells post-operation can cause rapid regrowth, and a reoperation can be more detrimental to the patient (Rosenthal et al, 2016). Up to 30% of breast cancer patients must undergo an additional surgery after a lumpectomy (Rodriguez et al, 2017). After surgical resection of gastrointestinal stromal tumors, 19% of patients had positive margins, and 40% of patients had tumor recurrence (DeMatteo et al, 2000).…”

Section: In Vitro Diagnostics: Nanoparticles For Biosensing Assaysmentioning

confidence: 99%

A path toward the clinical translation of nano‐based imaging contrast agents

Miyasato

Mohamed

Zavaleta

2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Recently, nanoparticles have evolved ubiquitously in therapeutic applications to treat a range of diseases. Despite their regular use as therapeutic agents in the clinic, we have yet to see much progress in their clinical translation as diagnostic imaging agents. Several clinical and preclinical studies support their use as imaging contrast agents, but their use in the clinical setting has been limited to off‐label imaging procedures (i.e., Feraheme). Since diagnostic imaging has been historically used as an exploratory tool to rule out disease or to screen patients for various cancers, nanoparticle toxicity remains a concern, especially when introducing exogenous contrast agents into a potentially healthy patient population, perhaps rationalizing why several nano‐based therapeutic agents have been clinically translated before nano‐based imaging agents. Another potential hindrance toward their clinical translation could be their market potential, as most therapeutic drugs have higher earning potential than small‐molecule imaging contrast agents. With these considerations in mind, perhaps a clinical path forward for nano‐based imaging contrast agents is to help guide/manage therapy. Several studies have demonstrated the ability of nanoparticles to produce more accurate imaging preoperatively, intraoperatively, and postoperatively. These applications illustrate a more reliable method of cancer detection and treatment that can prevent incomplete tumor resection and incorrect assessment of tumor progression following treatment. The aim of this review is to highlight the research that supports the use of nanoparticles in biomedical imaging applications and offer a new perspective to illustrate how nano‐based imaging agents have the potential to better inform therapeutic decisions. This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging

show abstract

Section: In Vitro Diagnostics: Nanoparticles For Biosensing Assaysmentioning

confidence: 99%